UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
12
November 2025 - “Director/PDMR
Shareholding”
|
99.1
Haleon plc: Director/PDMR
Shareholding
12 November 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by
Persons Discharging Managerial Responsibilities
("PDMRs").
On 12 November 2025, the Company received notification of the
following transactions as detailed below.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||||
|
a)
|
Name
|
Adrian
Morris
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
General
Counsel - PDMR
|
|||
|
b)
|
Initial notification /Amendment
|
Initial
Notification
|
|||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
||||
|
a)
|
Name
|
Haleon
plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary
Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification
code
|
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Acquisition
of Partnership Shares and award of Matching Shares under the
Company's Share Reward Plan
|
|||
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.718992
|
33
|
|
|
|
|
|
£Nil
|
33
(Matching Shares)
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|||
|
|
|
||||
|
- Aggregated volume
|
66
|
||||
|
|
|
||||
|
- Price
|
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
11 November 2025
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||||
|
a)
|
Name
|
Tamara
Rogers
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief
Marketing Officer - PDMR
|
|||
|
b)
|
Initial notification /Amendment
|
Initial
Notification
|
|||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
||||
|
a)
|
Name
|
Haleon
plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification
code
|
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares
under the Company's Share Reward Plan
|
|||
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.718992
|
33
|
|
|
|
|
|
£Nil
|
33
(Matching Shares)
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|||
|
|
|
||||
|
- Aggregated volume
|
66
|
||||
|
|
|
||||
|
- Price
|
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
11 November 2025
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
November 12, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|